The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
deoxycytidine Abbreviated in shorthand with dC. One of the four standard deoxyribonucleosides used in DNA molecules, consisting of a cytosine base with its N9 nitrogen bonded to the C1 carbon of a deoxyribose sugar. Cytosine bonded to ribose forms an alternate compound known simply as cytidine, which is used in RNA.
If a mutation is present in a germ cell, it can give rise to offspring that carries the mutation in all of its cells. This is the case in hereditary diseases. In particular, if there is a mutation in a DNA repair gene within a germ cell, humans carrying such germline mutations may have an increased risk of cancer. A list of 34 such germline mutations is given in the article DNA repair-deficiency disorder. An example of one is albinism, a mutation that occurs in the OCA1 or OCA2 gene. Individuals with this disorder are more prone to many types of cancers, other disorders and have impaired vision. DNA damage can cause an error when the DNA is replicated, and this error of replication can cause a gene mutation that, in turn, could cause a genetic disorder. DNA damages are repaired by the DNA repair system of the cell. Each cell has a number of pathways through which enzymes recognize and repair damages in DNA. Because DNA can be damaged in many ways, the process of DNA repair is an important way in which the body protects itself from disease. Once DNA damage has given rise to a mutation, the mutation cannot be repaired.
From then on, Suhner ran the business by himself. Studer, on the other hand, went on to found his own company "Willi Studer", known as Studer today and famous for its audio equipment. In 1968, Bertold Suhner resigned from his post in the operational management of Metrohm and became strongly committed to the environment. He even fought for causes that could harm his own company, making it a difficult time for the new managing directors Lorenz Kuhn and Hans Winzeler. As a result of his intransigence in environmental matters, he also alienated friends, leaving him socially isolated towards the end of his life. Since 1982, Metrohm AG has been a full subsidiary of the Metrohm Foundation, which is the only shareholder of Metrohm AG. Metrohm co-founder Bertold Suhner put the foundation in place to ensure independence and thereby maintain the ability to make unswayed decisions. The foundation is not only dedicated to the operation of Metrohm AG, but also to charitable and cultural purposes. For example, in 1999, the Metrohm Foundation equipped the public gymnasium Kantonsschule Trogen in the Swiss town of Trogen with internet access and more than 100 computer workstations to ensure that the public school can keep up with international standards. It has also endowed a professorship for the research on new materials at the Zurich University of Applied Sciences since 2014. Until 2006, 36 subsidiaries had been founded. For the most part, these are situated abroad and form a worldwide support and sales network.
Some endocrinologists and clinicians include the paracrine system as part of the endocrine system, but there is not consensus. Paracrines are slower acting, targeting cells in the same tissue or organ. An example of this is somatostatin which is released by some pancreatic cells and targets other pancreatic cells.
One condition that can affect the pharmacological properties of drugs is protein degradation caused by spaceflight, predicted to be associated with adaptive downsizing of the antigravity muscles and the energy deficit. This is seen in other responses, such as fight-or-flight, the presence of a new pathogen or virus, or some sort of injury to the body. Other conditions that affect the pharmacological capabilities of drugs are hypoxia, where drug antagonism is almost negligible in lower blood oxygen levels and physiologic enzyme conditions are limited in high oxygen tension conditions. In addition, diuretics cans shift the oxygen-hemoglobin curve, affecting drug performance.
Sources: en.wikipedia.org
== Honours and awards == Robinson was awarded the American Society for Mass Spectrometry's Biemann Medal in 2003, and the Christian B. Anfinsen Award in 2008. In 2004, the Royal Society awarded her both a Fellowship (FRS) and the Rosalind Franklin Award. Her citation for the Royal Society reads:
== Pharmacodynamics == AM404 is a weak agonist of cannabinoid receptors CB1 and CB2, an inhibitor of endocannabinoid transporter, a potent activator of TRPV1, and a very potent inhibitor of Nav1.8 and 1.7. It weakly inhibits cyclooxygenases (COX). The endocannbinoid system, TRPV1, and COX are involved in pain and thermoregulatory pathways. Nav1.8 and 1.7 are involved in peripheral pain perception.
The JWP considered that the JINR–LLNL collaborations of 2004 and 2007, producing element 113 as the daughter of element 115, did not meet the discovery criteria as they had not convincingly determined the atomic numbers of their nuclides through cross-bombardments, which were considered necessary since their decay chains were not anchored to previously known nuclides. They also considered that the previous JWP's concerns over their chemical identification of the dubnium daughter had not been adequately addressed. The JWP recognised the JINR–LLNL–ORNL–Vanderbilt collaboration of 2010 as having discovered elements 117 and 115, and accepted that element 113 had been produced as their daughter, but did not give this work shared credit. After the publication of the JWP reports, Sergey Dimitriev, the lab director of the Flerov lab at the JINR where the discoveries were made, remarked that he was happy with IUPAC's decision, mentioning the time Riken spent on their experiment and their good relations with Morita, who had learnt the basics of synthesising superheavy elements at the JINR. The sum argument advanced by the JWP in the approval of the discovery of element 113 was later criticised in a May 2016 study from Lund University and the GSI, as it is only valid if no gamma decay or internal conversion takes place along the decay chain, which is not likely for odd nuclei, and the uncertainty of the alpha decay energies measured in the 278113 decay chain was not small enough to rule out this possibility.
== Diagnosis == Diagnosis is fourfold: History and physical examination, elevation of creatine kinase, electromyograph (EMG) alteration, and a positive muscle biopsy. The hallmark clinical feature of polymyositis is proximal muscle weakness, with less important findings being muscle pain and dysphagia. Cardiac and pulmonary findings will be present in approximately 25% of cases of patients with polymyositis. Sporadic inclusion body myositis (sIBM) is often misdiagnosed as polymyositis or dermatomyositis but it can be differentiated as myositis that does not respond to treatment is likely IBM. sIBM comes on over months to years; polymyositis comes on over weeks to months. Polymyositis tends to respond well to treatment, at least initially; IBM does not.
Homocysteine (symbol Hcy) is a non-proteinogenic α-amino acid. It is a homologue of the amino acid cysteine, differing by an additional methylene bridge (−CH2−). It is biosynthesized from methionine by the removal of its terminal Cε methyl group. Although the production of homocysteine is a normal part of the metabolism of methionine, an excess of homocysteine can be harmful. There are two primary ways for organisms such as humans to metabolize homocysteine: remethylation and transsulfuration. Remethylation adds a methyl group to the homocysteine molecule, converting homocysteine back into methionine. There are two known remethylation pathways. One pathway requires vitamin B9 (folate) and B12 (cobalamin), which drive the MTR (methionine synthase) and MTRR (methionine synthase reductase) enzymes. The other pathway uses TMG (trimethylglycine) to drive the BHMT (betaine-homocysteine methyltransferase) enzyme. Transsulfuration converts homocysteine to cystathionine. This pathway requires vitamin B6 to drive the CBS (cystathionine beta synthase) enzyme. Cystathionine is the immediate precursor of the amino acid cysteine, which (along with glutamate and glycine), is incorporated into the tripeptide glutathione, a major antioxidant in the human body. Homocysteine is therefore an important metabolic substrate. However, excessive levels of homocysteine can result in hyperhomocysteinemia, which is regarded as an indicator of cardiovascular disease risk. Homocysteine likely contributes to atherogenesis, which can result in ischemic injury.
Sources: en.wikipedia.org
=== Right of employer to oppose unions === The act revised the Wagner Act's requirement of employer neutrality, to allow employers to deliver anti-union messages in the workplace. These changes confirmed an earlier Supreme Court ruling that employers have a constitutional right to express their opposition to unions, so long as they did not threaten employees with reprisals for their union activities nor offer any incentives to employees as an alternative to unionizing. The amendments also gave employers the right to file a petition asking the board to determine if a union represents a majority of its employees, and allow employees to petition either to decertify their union, or to invalidate the union security provisions of any existing collective bargaining agreement.
=== Meiosis === When C. brunneus was exposed to X-irradiation during the zygotene-early pachytene stages of meiosis, this treatment caused a significant increase in meiotic cell chiasma frequency. Chiasma frequency was scored during the subsequent diplotene-diakinesis stages of meiosis.
=== Membrane proteins === Multi-monoubiquitylation can mark transmembrane proteins (for example, receptors) for removal from membranes (internalisation) and fulfil several signalling roles within the cell. When cell-surface transmembrane molecules are tagged with ubiquitin, the subcellular localization of the protein is altered, often targeting the protein for destruction in lysosomes. This serves as a negative feedback mechanism, because often the stimulation of receptors by ligands increases their rate of ubiquitylation and internalisation. Like monoubiquitylation, lysine 63-linked polyubiquitin chains also has a role in the trafficking some membrane proteins.
== History == The group first came to the attention of record label Double T when they were finalist at Humo's Rock Rally, a prestigious Belgian rock contest, in 1996. Their first album was 1998's Little Things Of Venom (retitled At The Close Of Every Day for release in the United States). In 1999, after this album's success, they toured with Suede as well as opening for popular fellow Belgian band K's Choice. The following year they opened for Counting Crows on that band's European tour. 2001 brought extra fame for lead singer Steverlinck, who starred in the IMAX 3-D film Haunted Castle alongside Harry Shearer. The film also featured music by the band during the opening and closing credits. In 2002 the band released a second studio album, All Is Quiet Now, which was soon followed by a live album (Live in 2003). In 2008 their third studio album All Things Come in Waves was released. In 2009 Steverlinck was chosen by Arjen Lucassen as lead singer for a side project called Guilt Machine. 2010 saw the release of their fourth studio album Under the Cold Street Lights.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.